---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-059127"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-05-19T21:17:03+00:00"
generated_at: "2026-05-19T21:19:58.017206+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxart files preliminary proxy; urges support for board nominees amid dissident challenge

## Summary
- Annual meeting set for July 16, 2026; preliminary proxy filed with SEC.
- Dissident shareholder group nominated three candidates; company says they lack relevant biotech experience.
- Cash resources ~$61M as of Q1 2026; funded runway into Q2 2027.
- BARDA COVID-19 Phase 2b trial restored after stop-work order; main cohort primary readout expected early 2027.
- CEO holds over 2.5M shares and has never sold a share; board added Dr. James Breitmeyer in 2025.

## SEC filing metadata
- accession: 0001213900-26-059127
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-05-19T21:17:03+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000121390026059127/0001213900-26-059127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000121390026059127/ea0291449-8k_vaxart.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-059127
- JSON: https://secwatch.observer/filing/0001213900-26-059127.json
- Plain text: https://secwatch.observer/filing/0001213900-26-059127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.